Blueprint, Wellcome Trust Sanger, Mass General Collaborate on Identifying Cancer Targets | GenomeWeb

NEW YORK (GenomeWeb News) – Blueprint Medicines today announced a collaboration with Wellcome Trust Sanger Institute and the Massachusetts General Hospital Cancer Center to identify new cancer targets.

The partnership will use Sanger Institute's and Mass General's extensive human cancer cell line panel and BluePrint's next-generation, highly selective kinase inhibitor compounds. Cambridge, Mass.-based Blueprint is developing the kinase inhibitors for treating genetic abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.